Cempra has two antibiotic candidates, solithromycin (CEM-101) and TAKSTA™ (CEM-102, sodium fusidate), in clinical trials. Both target the growing problem of antimicrobial resistance.
Solithromycin is a next-generation macrolide, the first fluorok...查看全文
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-09-28 AccNo: 0001193125-17-297851 Size: 67 KB 网页链接
$Cempra, Inc.(CEMP)$ 8-K - Current report Filed: 2017-09-28 AccNo: 0001193125-17-297849 Size: 67 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-09-28 AccNo: 0001193125-17-296650 Size: 60 KB 网页链接
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-09-12 AccNo: 0001193125-17-282829 Size: 82 KB 网页链接
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-09-11 AccNo: 0001193125-17-281202 Size: 12 MB 网页链接
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-09-11 AccNo: 0001193125-17-281202 Size: 12 MB 网页链接
$Cempra, Inc.(CEMP)$ 8-K - Current report Filed: 2017-09-11 AccNo: 0001193125-17-281197 Size: 12 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Cempra, Inc.(CEMP)$ 8-K - Current report Filed: 2017-09-11 AccNo: 0001193125-17-281197 Size: 12 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-09-07 AccNo: 0001193125-17-279305 Size: 55 KB 网页链接
$Cempra, Inc.(CEMP)$ 8-K - Current report Filed: 2017-09-07 AccNo: 0001193125-17-279304 Size: 56 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接